Teddy Kosoglou

2.8k total citations
65 papers, 2.2k citations indexed

About

Teddy Kosoglou is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Oncology. According to data from OpenAlex, Teddy Kosoglou has authored 65 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Cardiology and Cardiovascular Medicine, 15 papers in Surgery and 12 papers in Oncology. Recurrent topics in Teddy Kosoglou's work include Antiplatelet Therapy and Cardiovascular Diseases (14 papers), Lipoproteins and Cardiovascular Health (13 papers) and Synthesis of β-Lactam Compounds (10 papers). Teddy Kosoglou is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (14 papers), Lipoproteins and Cardiovascular Health (13 papers) and Synthesis of β-Lactam Compounds (10 papers). Teddy Kosoglou collaborates with scholars based in United States, New Zealand and United Kingdom. Teddy Kosoglou's co-authors include Paul Statkevich, Kevin B. Alton, Amy O. Johnson‐Levonas, Arthur Bergman, John F. Paolini, David L. Cutler, Melton B. Affrime, Eric A. Espiner, Mark Richards and Christopher J. Charles and has published in prestigious journals such as Circulation, CHEST Journal and Hypertension.

In The Last Decade

Teddy Kosoglou

65 papers receiving 2.0k citations

Peers

Countries citing papers authored by Teddy Kosoglou

Since Specialization

Citations

This map shows the geographic impact of Teddy Kosoglou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Teddy Kosoglou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Teddy Kosoglou more than expected).

Fields of papers citing papers by Teddy Kosoglou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Teddy Kosoglou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Teddy Kosoglou. The network helps show where Teddy Kosoglou may publish in the future.

Co-authorship network of co-authors of Teddy Kosoglou

This figure shows the co-authorship network connecting the top 25 collaborators of Teddy Kosoglou. A scholar is included among the top collaborators of Teddy Kosoglou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Teddy Kosoglou. Teddy Kosoglou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Vorapaxar, an oral PAR‐1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone 2014 ·Clinical Pharmacology in Drug Development ·Teddy Kosoglou, (unknown), Paul Statkevich, (unknown), Bhavna Kantesaria, Mary E. Hanson, Christine McCrary Sisk, David L. Cutler	2
2	Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease 2013 ·International Journal of COPD ·Teddy Kosoglou, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	10
3	Hypothalamic-Pituitary-Adrenal Axis Effects of Mometasone Furoate/Formoterol Fumarate vs Fluticasone Propionate/Salmeterol Administered Through Metered-Dose Inhaler 2013 ·CHEST Journal ·Teddy Kosoglou, James Hubbell, David L. Cutler, Amy O. Johnson‐Levonas, Danlin Xu, Bhavna Kantesaria, Kenneth Kim, S. David Miller	4
4	Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment 2012 ·European Journal of Clinical Pharmacology ·Paul Statkevich, Teddy Kosoglou, Richard A. Preston, (unknown), Fengjuan Xuan, (unknown), (unknown), Ronald B. Langdon, David L. Cutler	22
5	Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin 2012 ·European Journal of Clinical Pharmacology ·Teddy Kosoglou, Yali Zhu, Fengjuan Xuan, (unknown), Amy O. Johnson‐Levonas, Monika Martinho, Paul Statkevich, David L. Cutler	10
6	Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects 2011 ·European Journal of Clinical Pharmacology ·Teddy Kosoglou, Larisa Reyderman, Renger G. Tiessen, A.A. van Vliet, (unknown), Robert B. Keller, (unknown), David L. Cutler	76
7	Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects 2010 ·European Journal of Clinical Pharmacology ·Teddy Kosoglou, Yali Zhu, Paul Statkevich, (unknown), (unknown), Fengjuan Xuan, (unknown), David L. Cutler	10
8	Effects of Ezetimibe on Cyclosporine Pharmacokinetics in Healthy Subjects 2006 ·The Journal of Clinical Pharmacology ·Arthur Bergman, Joanne Burke, Patrick Larson, (unknown), Larisa Reyderman, Paul Statkevich, Teddy Kosoglou, Howard Greenberg, Walter K. Kraft, (unknown), Gail Murphy, Keith Gottesdiener, John F. Paolini	23
9	The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe 2005 ·Current Medical Research and Opinion ·Larisa Reyderman, Teddy Kosoglou, David L. Cutler, Stephen E. Maxwell, Paul Statkevich	14
10	Ezetimibe 2005 ·Clinical Pharmacokinetics ·Teddy Kosoglou, Paul Statkevich, Amy O. Johnson‐Levonas, John F. Paolini, Arthur Bergman, Kevin B. Alton	364
11	Pharmacodynamic interaction between ezetimibe and rosuvastatin 2004 ·Current Medical Research and Opinion ·Teddy Kosoglou, Paul Statkevich, Bo Yang, Ramachandran Suresh, Yali Zhu, (unknown), Stephen E. Maxwell, Renger G. Tiessen, David L. Cutler	49
12	Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers* 2004 ·Current Medical Research and Opinion ·Larisa Reyderman, Teddy Kosoglou, (unknown), Michael Seiberling, Paul Statkevich	13
13	Pharmacodynamic and pharmaco-kinetic interaction between fenofibrate and ezetimibe* 2004 ·Current Medical Research and Opinion ·Teddy Kosoglou, Paul Statkevich, Jean‐Charles Fruchart, (unknown), Larisa Reyderman, David L. Cutler, Michel Guillaume, Stephen E. Maxwell, Enrico P. Veltri	50
14	Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin 2002 ·British Journal of Clinical Pharmacology ·Teddy Kosoglou, Ingo Meyer, Enrico P. Veltri, Paul Statkevich, Bo Yang, Yali Zhu, L. Mellars, Stephen E. Maxwell, James E. Patrick, David L. Cutler, Vijay Batra, Melton B. Affrime	91
15	Ezetimibe does not affect the pharmacokinetics of oral contraceptives 2001 ·Clinical Pharmacology & Therapeutics ·Anther Keung, Teddy Kosoglou, Paul Statkevich, Lesley Anderson, (unknown), David L. Cutler, Vishal Batra, Edward M. Sellers	27
16	A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe 2001 ·Clinical Therapeutics ·Farkad Ezzet, Gopal Krishna, David Wexler, Paul Statkevich, Teddy Kosoglou, Vijay Batra	100
17	Mometasone Furoate Has Minimal Effects on the Hypothalamic-Pituitary-Adrenal Axis When Delivered at High Doses 2000 ·CHEST Journal ·Melton B. Affrime, Teddy Kosoglou, C. Mohan Thonoor, (unknown), Jerry Herron	73
18	Combined Neutral Endopeptidase and Angiotensin-Converting Enzyme Inhibition in Heart Failure: Role of Natriuretic Peptides and Angiotensin II 1998 ·Journal of Cardiovascular Pharmacology ·Miriam T. Rademaker, Christopher J. Charles, Eric A. Espiner, M. Gary Nicholls, Mark Richards, Teddy Kosoglou	59
19	Influence of Food on the Oral Bioavailability of Loratadine and Pseudoephedrine from Extended‐Release Tablets in Healthy Volunteers 1996 ·The Journal of Clinical Pharmacology ·Amin A. Nomeir, Parviz Mojaverian, Teddy Kosoglou, Melton B. Affrime, (unknown), (unknown), Chin‐Chung Lin, Mitchell N. Cayen	17
20	Trimethoprim alters the disposition of procainamide and N-acetylprocainamide 1988 ·Clinical Pharmacology & Therapeutics ·Teddy Kosoglou, Mario L. Rocci, Peter H. Vlasses	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact